Translation: Original published in Finnish on 07/15/2026 at 07:30 am EEST

Nexstim announced on Thursday that it had received a new order for ten NBS 6 systems from its distributor. The systems will be delivered during the second half of the current year. Nexstim's news flow has been positive recently, as it   announced a similar order for ten systems, likely from the same distributor, just a month ago. The repeated large order reinforces our view of the distribution channel's strong momentum and provides significant support for our current year estimates.

A repeated large one-off order strengthens the power of the distribution partnership

According to the release, the ordered systems, like the previous order, include both diagnostic and therapeutic features. Although Nexstim did not name the distributor in the press release, we consider it likely to be the company's strategic partner, Brainlab. The first order for ten systems, announced in June, was already the largest in Nexstim's history, and this second similar order is a very strong signal of the rapid scaling of the collaboration. Last year, Nexstim delivered a total of 37 systems, so we feel that the 20 systems ordered for the current year through this distributor alone represent a large volume for the company. This strengthens our confidence that the Brainlab collaboration will yield results in a relatively short timeframe.

The growth outlook for the rest of the year looks good

All ten systems now ordered will be delivered during H2. We have been expecting system sales to pick up significantly towards the end of the year, and this order, combined with the previous one, provides support for our expectations. We expect the company's full-year 2026 revenue to grow by nearly 16% to 12.7 MEUR. According to our preliminary assessment, the company is now well-positioned to achieve our estimated growth rate, and there may be slight upward pressure on our estimates.

In addition to these orders, Nexstim received Malaysian sales authorization  for the NBS system 6 in early July and soon recorded its first sales in the country, opening a new market in Southeast Asia. In addition,  Health Canada's expanded approval  extends NBS 6's indications in Canada beyond major depressive disorder (MDD) to diagnostics and chronic neuropathic pain. These support the view of the company's expansion into new markets and new indications.